# GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

> **NCT04405375** · PHASE2 · UNKNOWN · sponsor: **Beijing Tongren Hospital** · enrollment: 29 (estimated)

## Conditions studied

- Extranodal NK/T-cell Lymphoma, Nasal Type

## Interventions

- **DRUG:** gemcitabin
- **DRUG:** Pegaspargase
- **DRUG:** Etoposide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04405375
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-21
- **Primary completion:** 2023-04-30
- **Final completion:** 2023-04-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2020-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04405375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04405375, "GPED Regimen for Relapsed/Refractory or Advanced ENKTCL". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04405375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*